December 4, 2023
Home Posts tagged COVID-19
Health Lifestyle

Tevogen Bio to Study Therapeutic Potential of its Investigational COVID-19 T Cell Therapy in Long COVID

WARREN, N.J.: Tevogen Bio, a late-stage clinical biotechnology company specializing in the development of cellular immunotherapies in oncology, neurology, and virology announced today its intention to study potential therapeutic use of its investigational COVID-19 T cell therapy, TVGN-489, in Long COVID. The finding that none of the patients in the TVGN 489

Inflation in Dubai and Europe

Dubai, United Arab Emirates — A toxic recession impeded global economic growth in 2022, as disadvantageous COVID-19 pandemic effects and the muddle of limited energy supplies were magnified by macropolitical uncertainty and red-hot inflation. This led to skyrocketing oil & gas prices in Europe. The continent was hit hard, as much of its energy supplies […]

Digital Transformation During and Beyond Covid-19

By: Naji Kazak, Managing Director- EMEA at Kodak Alaris   COVID-19 has been a massive catalyst for digital transformation, but companies need to do more than implement short-term solutions that enable remote work. Businesses with an eye to fully automated workflows will enjoy benefits that far outlast the pandemic. Work From Home – Work Must […]

Culture: The Department of Culture and Tourism – Abu Dhabi and UNESCO launch a new report on the economic impact of COVID-19

Abu Dhabi, 27 June 2022 —The Department of Culture and Tourism – Abu Dhabi and the UNESCO launched today the co-publication Culture in Times of COVID-19: Resilience, Recovery and Revival, giving a global overview of the impact of the pandemic on the culture sector since March 2020, and outlining directions for its revival. During the […]

Evusheld significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations

Detailed results from the PROVENT Phase III pre-exposure prophylaxis (prevention) trial showed that AstraZeneca’s Evusheld (tixagevimab and cilgavimab), formerly AZD7442, reduced the risk of developing symptomatic COVID-19 by 77% in the primary analysis and by 83% in the six month follow-up analysis, compared to placebo. There were no cases of severe disease or COVID-19